Literature DB >> 31456362

Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation.

Sijin Guo1,2,3,4, Congcong Xu1,2,3,4, Hongran Yin1,2,3,4, Jordan Hill5, Fengmei Pi5, Peixuan Guo1,2,3,4.   

Abstract

The past decade has shown exponential growth in the field of RNA nanotechnology. The rapid advances of using RNA nanoparticles for biomedical applications, especially targeted cancer therapy, suggest its potential as a new generation of drug. After the first milestone of small molecule drugs and the second milestone of antibody drugs, it was predicted that RNA drugs, either RNA itself or chemicals/ligands that target RNA, will be the third milestone in drug development. Thus, a comprehensive assessment of the current therapeutic RNA nanoparticles is urgently needed to meet the drug evaluation criteria. Specifically, the pharmacological and immunological profiles of RNA nanoparticles need to be systematically studied to provide insights in rational design of RNA-based therapeutics. By virtue of its programmability and biocompatibility, RNA molecules can be designed to construct sophisticated nanoparticles with versatile functions/applications and highly tunable physicochemical properties. This intrinsic characteristic allows the systemic study of the effects of various properties of RNA nanoparticles on their in vivo behaviors such as cancer targeting and immune responses. This review will focus on the recent progress of RNA nanoparticles in cancer targeting, and summarize the effects of common physicochemical properties such as size and shape on the RNA nanoparticles' biodistribution and immunostimulation profiles. This article is categorized under: Biology-Inspired Nanomaterials > Nucleic Acid-Based Structures Diagnostic Tools > in vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  RNA nanoparticle; RNA nanostructure; RNA nanotechnology; biodistribution; immune response; immunomodulation; immunostimulation; nanobiotechnology

Year:  2019        PMID: 31456362      PMCID: PMC6908753          DOI: 10.1002/wnan.1582

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  123 in total

1.  TectoRNA: modular assembly units for the construction of RNA nano-objects.

Authors:  L Jaeger; E Westhof; N B Leontis
Journal:  Nucleic Acids Res       Date:  2001-01-15       Impact factor: 16.971

2.  Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery.

Authors:  Sherine Abdelmawla; Songchuan Guo; Limin Zhang; Sai M Pulukuri; Prithviraj Patankar; Patrick Conley; Joseph Trebley; Peixuan Guo; Qi-Xiang Li
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

Review 3.  The emerging field of RNA nanotechnology.

Authors:  Peixuan Guo
Journal:  Nat Nanotechnol       Date:  2010-11-21       Impact factor: 39.213

4.  Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs.

Authors:  Qing Ge; Anne Dallas; Heini Ilves; Joshua Shorenstein; Mark A Behlke; Brian H Johnston
Journal:  RNA       Date:  2009-11-30       Impact factor: 4.942

Review 5.  Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.

Authors:  Peng Zhang; Fang Sun; Sijun Liu; Shaoyi Jiang
Journal:  J Control Release       Date:  2016-06-28       Impact factor: 9.776

Review 6.  Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.

Authors:  Marina A Dobrovolskaia
Journal:  J Control Release       Date:  2015-09-05       Impact factor: 9.776

7.  Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles.

Authors:  Kirill A Afonin; Mathias Viard; Ioannis Kagiampakis; Christopher L Case; Marina A Dobrovolskaia; Jen Hofmann; Ashlee Vrzak; Maria Kireeva; Wojciech K Kasprzak; Vineet N KewalRamani; Bruce A Shapiro
Journal:  ACS Nano       Date:  2014-12-18       Impact factor: 15.881

8.  RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.

Authors:  Tae Jin Lee; Farzin Haque; Dan Shu; Ji Young Yoo; Hui Li; Robert A Yokel; Craig Horbinski; Tae Hyong Kim; Sung-Hak Kim; Chang-Hyuk Kwon; Ichiro Nakano; Balveen Kaur; Peixuan Guo; Carlo M Croce
Journal:  Oncotarget       Date:  2015-06-20

9.  Margination of micro- and nano-particles in blood flow and its effect on drug delivery.

Authors:  Kathrin Müller; Dmitry A Fedosov; Gerhard Gompper
Journal:  Sci Rep       Date:  2014-05-02       Impact factor: 4.379

10.  Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2'-F RNA, and LNA in the context of Phi29 pRNA 3WJ.

Authors:  Xijun Piao; Hongzhi Wang; Daniel W Binzel; Peixuan Guo
Journal:  RNA       Date:  2017-10-19       Impact factor: 4.942

View more
  14 in total

1.  RNA Nanoparticles as Rubber for Compelling Vessel Extravasation to Enhance Tumor Targeting and for Fast Renal Excretion to Reduce Toxicity.

Authors:  Chiran Ghimire; Hongzhi Wang; Hui Li; Mario Vieweger; Congcong Xu; Peixuan Guo
Journal:  ACS Nano       Date:  2020-09-16       Impact factor: 15.881

Review 2.  The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development.

Authors:  Xin Li; Abhjeet S Bhullar; Daniel W Binzel; Peixuan Guo
Journal:  Adv Drug Deliv Rev       Date:  2022-05-05       Impact factor: 17.873

3.  Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice.

Authors:  Alice Braga; Sara Bandiera; Jeroen Verheyen; Regan Hamel; Carola Rutigliani; Frank Edenhofer; Jayden Aaron Smith; Stefano Pluchino
Journal:  Mol Ther       Date:  2020-08-05       Impact factor: 11.454

4.  Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.

Authors:  Ridhima Juneja; Hemapriyadarshini Vadarevu; Justin Halman; Mubin Tarannum; Lauren Rackley; Jacob Dobbs; Jose Marquez; Morgan Chandler; Kirill Afonin; Juan L Vivero-Escoto
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-18       Impact factor: 9.229

5.  Discovery of Plasma Membrane-Associated RNAs through APEX-seq.

Authors:  Erzhong Wu; Xuzhen Guo; Xueyi Teng; Ruijin Zhang; Fahui Li; Ya Cui; Dongdong Zhang; Qinghua Liu; Jianjun Luo; Jiangyun Wang; Runsheng Chen
Journal:  Cell Biochem Biophys       Date:  2021-05-24       Impact factor: 2.194

Review 6.  Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine-Specific Cancer Targeting with Undetectable Toxicity.

Authors:  Daniel W Binzel; Xin Li; Nicolas Burns; Eshan Khan; Wen-Jui Lee; Li-Ching Chen; Satheesh Ellipilli; Wayne Miles; Yuan Soon Ho; Peixuan Guo
Journal:  Chem Rev       Date:  2021-05-26       Impact factor: 72.087

7.  Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer.

Authors:  Zhefeng Li; Linlin Yang; Hongzhi Wang; Daniel W Binzel; Terence M Williams; Peixuan Guo
Journal:  Nucleic Acid Ther       Date:  2021-05-17       Impact factor: 4.244

Review 8.  Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology.

Authors:  Yuhua Weng; Qianqian Huang; Chunhui Li; Yongfeng Yang; Xiaoxia Wang; Jie Yu; Yuanyu Huang; Xing-Jie Liang
Journal:  Mol Ther Nucleic Acids       Date:  2019-12-17       Impact factor: 8.886

Review 9.  Advances in Oral Subunit Vaccine Design.

Authors:  Hans Van der Weken; Eric Cox; Bert Devriendt
Journal:  Vaccines (Basel)       Date:  2020-12-22

Review 10.  Targeting the "Sweet Side" of Tumor with Glycan-Binding Molecules Conjugated-Nanoparticles: Implications in Cancer Therapy and Diagnosis.

Authors:  Nora Bloise; Mohammad Okkeh; Elisa Restivo; Cristina Della Pina; Livia Visai
Journal:  Nanomaterials (Basel)       Date:  2021-01-22       Impact factor: 5.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.